← Dashboard
Stock
ABT
ABBOTT LABORATORIESHealth CareHealth Care EquipmentLatest close $889 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
9
27 funds tracked
Ever held
12
Current + past
New this quarter
3
Exited this quarter
0
Marquee-fund ownership over time
Nov 13, 2013May 11, 2017May 16, 2022May 15, 2026
Now
9
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q4 2013 | 51Q | $30 | $88 | +197% |
| Maverick Capital re-entered | Q4 2019 | 27Q | $75 | $88 | +18% |
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $105 | $88 | -16% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $106 | $88 | -17% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $106 | $88 | -17% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $106 | $88 | -17% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $106 | $88 | -17% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $106 | $88 | -17% |
| Soros Fund Management | Q2 2026(8Q snapshot) | 1Q | $84 | $88 | +4% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Glenview Capital | Q2 2020 | Q3 2020 | → $90 | +12% |
| Duquesne Family Office 2× in & out | Q4 2018 | Q3 2020 | → $90 | +48% |
| Third Point | Q1 2014 | Q2 2014 | → $31 | +2% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at ABBOTT LABORATORIES. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
19
Filings · last 90d
41
Total on file
720
Recent SEC buffer
Most recent
Apr 29, 2026
30d / 90d windows measured from Apr 29, 2026 — the most recent Form 4 on file — not from today.
- Form 40001783147-26-000009Apr 29, 2026
- Form 40001306119-26-000004Apr 28, 2026
- Form 40001385262-26-000012Apr 28, 2026
- Form 40000902132-26-000005Apr 28, 2026
- Form 40001577544-26-000006Apr 28, 2026
- Form 40001527742-26-000012Apr 28, 2026
- Form 40001294731-26-000004Apr 28, 2026
- Form 40001787479-26-000003Apr 28, 2026
- Form 40001640036-26-000004Apr 28, 2026
- Form 40001879701-26-000006Apr 28, 2026
- Form 40001537286-26-000002Apr 28, 2026
- Form 40001736637-26-000002Apr 28, 2026
- Form 40002102715-26-000004Apr 28, 2026
- Form 40001805099-26-000006Apr 27, 2026
- Form 40001385262-26-000010Apr 2, 2026
Showing 15 of 720 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · ABBOTT LABORATORIESAnnual figures sourced directly from ABBOTT LABORATORIES's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$44.33B
FY2025+6% YoY
Net income
$6.52B
FY2025-51% YoY
EPS (diluted)
$3.72
FY2025-51% YoY
Free cash flow(?)
$7.4B
FY2025+16% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for ABBOTT LABORATORIES — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportApr 29, 2026
- 8-KFORM 8-KApr 27, 2026
- 8-KFORM 8-KApr 17, 2026
- 8-KMaterial eventApr 16, 2026
- 8-KFORM 8-KMar 23, 2026
- DEF 14ADEFINITIVE PROXY STATEMENTMar 13, 2026
- 8-KFORM 8-KMar 9, 2026
- 8-KFORM 8-KFeb 26, 2026
- 8-KFORM 8-KFeb 20, 2026
- 10-KAnnual reportFeb 20, 2026
- 8-KMaterial eventJan 22, 2026
- 8-KFORM 8-KDec 12, 2025
- 8-KFORM 8-KNov 21, 2025
- 8-KFORM 8-KNov 20, 2025
- 10-QQuarterly reportOct 29, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Soros Fund Management | Q2 2026 | open | $84 | $88 | +4% |
| Two Sigma Investments | Q2 2026 | open | $84 | $88 | +4% |
| Maverick Capital | Q2 2026 | open | $84 | $87 | +3% |
| Renaissance Technologies | Q1 2026 | open | $111 | $88 | -21% |
| Citadel Advisors | Q4 2025 | open | $129 | $88 | -32% |
| Citadel Advisors | Q3 2024 | Q2 2025 | $106 | $131 | +23% |
| Two Sigma Investments | Q3 2024 | Q4 2025 | $106 | $129 | +22% |
| D.E. Shaw | Q3 2024 | open | $106 | $88 | -17% |
| AQR Capital Management | Q3 2024 | open | $106 | $88 | -17% |
| Millennium Management | Q3 2024 | open | $106 | $88 | -17% |
| Renaissance Technologies | Q3 2024 | Q4 2024 | $105 | $112 | +7% |
| Maverick Capital | Q4 2023 | Q2 2024 | $92 | $100 | +9% |
| Maverick Capital | Q2 2022 | Q3 2023 | $101 | $100 | -1% |
| Bridgewater Associates | Q4 2020 | open | $102 | $87 | -15% |
| Glenview Capital | Q2 2020 | Q3 2020 | $81 | $90 | +12% |
| Bridgewater Associates | Q2 2020 | Q3 2020 | $82 | $91 | +10% |
| Maverick Capital | Q4 2019 | Q1 2022 | $75 | $113 | +51% |
| Duquesne Family Office | Q4 2018 | Q3 2020 | $61 | $90 | +48% |
| Bridgewater Associates | Q4 2017 | Q1 2018 | $48 | $50 | +5% |
| Duquesne Family Office | Q3 2016 | Q1 2017 | $38 | $37 | -2% |
| Bridgewater Associates | Q3 2015 | Q2 2017 | $41 | $37 | -9% |
| Bridgewater Associates | Q1 2015 | Q2 2015 | $36 | $39 | +9% |
| Bridgewater Associates | Q2 2014 | Q4 2014 | $32 | $35 | +12% |
| Third Point | Q1 2014 | Q2 2014 | $31 | $31 | +2% |
| Bridgewater Associates | Q4 2013 | Q1 2014 | $30 | $30 | +2% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.